Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
SUMMARY: Background: Given the limited efficacy of current pharmacotherapy for major depressive disorder (MDD) and the historical decline in antidepressant development, there is increasing clinical urgency to develop more effective treatments. Objectives: To synthesize findings from clinical psychology and affective neuroscience related to the construct of emotional temperament; to examine the effects of antidepressants on the temperament dimensions of positive (PA) and negative affectivity (NA); and to propose a biobehavioral research paradigm for the treatment of MDD. Methods: We begin with an introduction to PA and NA, which emphasizes their construct development, historical context, and relevance to psychopathology. We then review studies of antidepressant effects on PA and NA, and explore two related hypotheses: (1) Cause‐correction: The antidepressant response may fundamentally occur through changes in emotional temperament, with subsequent spread to syndrome or symptom changes; (2) preferential effects: Antidepressants with different mechanisms of action may have preferential effects on PA or NA. Results: Preliminary findings appear to support the cause‐correction hypothesis; there is insufficient clinical evidence to support the preferential effects hypothesis. Conclusions: PA and NA are biologically based temperament dimensions, which modulate emotional, motivational, and behavioral responses to positive and negative incentives. They can be altered by antidepressants, and may independently contribute to depression improvement. In addition, the distinct biobehavioral features of PA and NA suggest that combined pharmacological and cognitive–behavioral treatments targeting these dimensions may have specific, and perhaps, synergistic antidepressant effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationBlood, A. J., & Zatorre, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191355898 · Cited by 2,814
Depue, R. A., & Collins, P. F. (1999) · Behavioral and Brain Sciences · doi:10.1017/s0140525x99002046 · Cited by 2,046
Comorbidity of anxiety and unipolar mood disorders
Mineka, S., Watson, D., & Clark, L. A. (1998) · Annual Review of Psychology · doi:10.1146/annurev.psych.49.1.377 · Cited by 1,573
Watson, D., Weber, K., Assenheimer, J. S., Clark, L. A., Strauss, M. E., & McCormick, R. A. (1995) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.104.1.3 · Cited by 1,423
Brown, T. A., Chorpita, B. F., & Barlow, D. H. (1998) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.107.2.179 · Cited by 1,400 · cited 2×
“Other potential benefits of the RDoC Project include: (1) Preservation of psychopathology and treatment data, which are currently lost by the exclusion of subthreshold disorders [31]; (2) Greater ability to account for high rates of comorbidity between anxiety and depressive disorders, which, as modeled by the IHHM, a…”
BackgroundPrefrontal Brain Asymmetry: A Biological Substrate of the Behavioral Approach and Inhibition Systems
Sutton, S. K., & Davidson, R. J. (1997) · Psychological Science · doi:10.1111/j.1467-9280.1997.tb00413.x · Cited by 1,263
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“ies also suggest that catecholamines—dopamine in particular—are prominently involved in impaired reward processing and that low PA represents a good candidate endophenotype for MDD [29].”
BackgroundThe Hamilton Depression Rating Scale: Has the Gold Standard Become a Lead Weight?
Bagby, R. M., Ryder, A. G., Schuller, D. R., & Marshall, M. B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.12.2163 · Cited by 1,148
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989 · cited 5×
“34], (2) the Behavioral Inhibition and Activation System Scales [35], (3) the Revised Personality Inventory and Five-Factor Inventory [NEO-FI; Ref.”
BackgroundMethodInfluentialTemperament as a unifying basis for personality and psychopathology.
Clark, L. A. (2005) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.114.4.505 · Cited by 796 · cited 2×
“It should also be noted that these constructs differ importantly from Cloninger’s tridimensional theory of temperament (“harm avoidance,” “reward dependence,” and “novelty seeking”), which may be limited by measures, such as the Tridimensional Personality Questionnaire and the Temperament and Character Inventory, with…”
BackgroundFu, C. H. Y., Williams, S. C. R., Cleare, A. J., Brammer, M. J., Walsh, N. D., Kim, J., Andrew, C. M., Pich, E. M., Williams, P. M., Reed, L. J., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.9.877 · Cited by 775
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
Drevets, W. C., Gautier, C., Price, J. C., Kupfer, D. J., Kinahan, P. E., Grace, A. A., Price, J. L., & Mathis, C. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01038-6 · Cited by 706 · cited 1×
“Amphetamine-induced increased release of dopamine in the ventral striatum is associated with increased PA [72], and radioligandbased positron-emission tomographic (PET) studies have found increased activity in dopamine-rich regions of the ventral striatum in response to rewarding stimuli [73–75].”
BackgroundBrown, T. A., & Barlow, D. H. (2009) · Psychological Assessment · doi:10.1037/a0016608 · Cited by 639
Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542 · cited 1×
“for synergistically combining pharmacological and psychological interventions [50].”
BackgroundSelective Alteration of Personality and Social Behavior by Serotonergic Intervention
Knutson, B., Wolkowitz, O. M., Cole, S. W., Chan, T., Moore, E. A., Johnson, R. C., Terpstra, J., Turner, R. A., & Reus, V. I. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.3.373 · Cited by 500 · cited 1×
“Knutson and colleagues conducted the first double-blind, RCT to investigate the hypothesis that SSRIs may have different effects on NA and PA in healthy individuals [58].”
BackgroundEffect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients
Harmer, C. J., O’Sullivan, U., Favaron, E., Massey-Chase, R., Ayres, R., Reinecke, A., Goodwin, G. M., & Cowen, P. J. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020149 · Cited by 485
Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues
Harmer, C. J., Mackay, C. E., Reid, C. B., Cowen, P. J., & Goodwin, G. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.015 · Cited by 450
Personality Change During Depression Treatment: A Placebo-Controlled Trial
Tang, T. Z., DeRubeis, R. J., Hollon, S. D., Amsterdam, J., Shelton, R., & Schalet, B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.166 · Cited by 384 · cited 2×
“However, there is growing support for the cause-correction hypothesis [43], which posits that changes in emotional temperament may cause, or independently contribute to depression improvement.”
BackgroundAbnormal temporal difference reward-learning signals in major depression
Kumar, P., Waiter, G., Ahearn, T., Milders, M., Reid, I., & Steele, J. D. (2008) · Brain · doi:10.1093/brain/awn136 · Cited by 374
Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study
Price, J., Cole, V., & Goodwin, G. M. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051110 · Cited by 362 · cited 14×
“Subjects with MDD receiving SSRIs exhibited greater trait NA change, as measured by neuroticism ratings on the NEO-PI, than those receiving noradrenergic and dopaminergic reuptake blockers (NDMs) or reversible monoamine oxidase inhibitors (RIMAs).”
BackgroundInfluentialWilamowska, Z. A., Thompson-Hollands, J., Fairholme, C. P., Ellard, K. K., Farchione, T. J., & Barlow, D. H. (2010) · Depression and Anxiety · doi:10.1002/da.20735 · Cited by 314
Brown, T. A. (2007) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.116.2.313 · Cited by 306
The relationship in experience between various types of affect.
Diener, E., & Iran-Nejad, A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.50.5.1031 · Cited by 279
Effect of a single dose of citalopram on amygdala response to emotional faces
Murphy, S. E., Norbury, R., O'Sullivan, U., Cowen, P. J., & Harmer, C. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.056093 · Cited by 255 · cited 1×
“Functional MRI performed 3 h after administration demonstrated a significantly reduced amygdala response to fearful facial expressions compared to placebo [47].”
BackgroundNeural representation of reward in recovered depressed patients
McCabe, C., Cowen, P. J., & Harmer, C. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1573-9 · Cited by 248
Remission and relapse in major depression: a two-year prospective follow-up study
Ramana, R., Paykel, E. S., Cooper, Z., Hayhurst, H., Saxty, M., & Surtees, P. G. (1995) · Psychological Medicine · doi:10.1017/s0033291700033134 · Cited by 236 · cited 1×
“Perhaps more problematic, between 40% and 60% of responders will relapse within 1 year [6,8].”
BackgroundHettema, J. M., Prescott, C. A., & Kendler, K. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1581 · Cited by 224 · cited 1×
“Twin studies have found a high degree of overlap between the genetic factors thought to underlie high NA, measured as neuroticism, and anxiety and depressive disorders [25,26].”
BackgroundBodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159
Apathy and Indifference in Patients on Fluvoxamine: and Fluoxetine
HOEHN-SARIC, R., LIPSEY, J. R., & McLEOD, D. R. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199010000-00007 · Cited by 156
Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., & Manber, R. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002870 · Cited by 147
Assessing the effects of bupropion SR on mood dimensions of depression
Tomarken, A. J., Dichter, G. S., Freid, C., Addington, S., & Shelton, R. C. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00306-3 · Cited by 139 · cited 1×
“The first double-blind, randomized trial to investigate antidepressant effects on low PA in MDD was conducted by Tomarken and colleagues [79].”
BackgroundMurphy, S. E., Yiend, J., Lester, K. J., Cowen, P. J., & Harmer, C. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009164 · Cited by 90 · cited 1×
“The early dampening effects of serotonergic antidepressants on NA and the related construct, negative emotional appraisal, have now been established in clinical [46,59] and nonclinical samples [48,60].”
BackgroundNK 1 receptor antagonism and emotional processing in healthy volunteers
Chandra, P., Hafizi, S., Massey-Chase, R., Goodwin, G., Cowen, P., & Harmer, C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109103101 · Cited by 30 · cited 1×
“Similar reductions in limbic reactivity have been found in healthy individuals treated with citalopram over 7 days [48], and the emotional processing effects of antidepressants have also been partially replicated with the neurokinin-1 (NK[1]) receptor antagonist, aprepitant [49].”
Background
Cited by
A systematic review of personality trait change through intervention.
Roberts, B. W., Luo, J., Briley, D. A., Chow, P. I., Su, R., & Hill, P. L. (2017) · Psychological Bulletin · doi:10.1037/bul0000088 · Cited by 1,047
The Nature, Diagnosis, and Treatment of Neuroticism: Back to the Future
Barlow, D. H., Sauer-Zavala, S., Carl, J. R., Bullis, J. R., & Ellard, K. K. (2014) · Clinical Psychological Science · doi:10.1177/2167702613505532 · Cited by 850
Self-citationKnowles, K. A., & Olatunji, B. O. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101928 · Cited by 420
Positive emotion regulation in emotional disorders: A theoretical review
Carl, J. R., Soskin, D. P., Kerns, C., & Barlow, D. H. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.01.003 · Cited by 391
Self-citationPersonalized prediction of antidepressant v. placebo response: evidence from the EMBARC study
Webb, C. A., Trivedi, M. H., Cohen, Z. D., Dillon, D. G., Fournier, J. C., Goer, F., Fava, M., McGrath, P. J., Weissman, M., Parsey, R., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001708 · Cited by 171
“Consistent with prior work, higher neuroticism was associated with greater response to SSRI relative to placebo, which may in part be due to the role of SSRIs in blunting negative affect (Quilty et al., 2008; Tang et al., 2009; Soskin et al., 2012).”
ResultSelf-citation
Metadata
- Authors
- Soskin, D. P., Carl, J. R., Alpert, J., & Fava, M.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2012-06
- Volume
- 18
- Issue
- 6
- Pages
- 441-451
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W1505100413
- Cited by
- 45
- References
- 34
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.